Aptilon revenues up $3.71 million in third quarter 2009

Aptilon Corporation ("Aptilon" or the "Company") (TSX-V: APZ), a leader in online marketing to physicians and healthcare professionals, today announced its financial results for the three and nine months ended September 30, 2009. Financial references are in CDN dollars unless otherwise indicated. Complete financial statements and MD&A are available on SEDAR at www.sedar.com.

Q3 2009 Summary - Revenues reached $3.71 million, compared to $1.66 million in Q3 2008 - Gross profit totaled $2.3 million compared to $1.1 million in Q3 2008 - YTD 2009 gross margin 69% compared to 66% in YTD 2008 - Net loss totaled ($613,760) (including $674,558 in non-cash charges(1)) compared to ($1.4 million) (including $357,141 in non- cash charges(1)) in Q3 2008 - Generated positive net cash flow from operations of $60,798 (before net change in non cash working capital item of ($25,771))

Financial Review

For the third quarter of 2009 revenues increased to $3,719,750 compared to $1,667,692 for the same period a year ago, an increase of 123%. Revenues for the first nine months of 2009 totaled $9,597,386 compared to $5,342,556 for the first nine months of 2008, an increase of 80%. Revenue in the period reflects a broader base of customers and growth in the size of enterprise customer initiatives.

Gross profit for the three-month period ended September 30, 2009 was $2,342,169 or 63% of revenue compared to $1,103,203 or 66% of revenue for the three months ended September 30, 2008. For the nine months ended September 30, 2009 gross profit increased to $6,579,332 or 69% of revenue compared to $3,369,780 or 63% of revenue for the same period in 2008. Gross margin improvements are primarily a result of increased operational efficiencies combined with the greater number of ongoing projects.

Sales and marketing expenses for the third quarter of 2009 totaled $1,259,905 compared to $1,246,975 for the third quarter of 2008, an increase of 1%. For the nine-month period ended September 30, 2009, sales and marketing expenses totaled $3,791,973 compared to $4,199,418 in the same period of 2008, a decrease of 10%.

General and administrative ("G&A") expenses for the third quarter of 2009 increased by 5% to $724,927 compared to $688,830 in the third quarter of 2008. G&A expenses for the first nine months of 2009 totaled $2,156,242 compared to $2,193,031 in same period of 2008, a decrease of 2%.

Overall, operating expenses increased 2%, from $2,556,489 for the three months ended September 30, 2008 to $2,617,451 for the three months ended September 30, 2009. For the nine months ended September 30, 2009, the reduction in operating expenses amounted to $36,789 or 2% compared to the nine months ended September 30, 2008. The decrease in expenses is due to ongoing Company-wide efforts to improve efficiency.

In the quarter ended September 30, 2009, the Company generated positive cash-flow from operations of $60,798 (before net change in non cash working capital item of ($25,771). In the year prior period, cash flows used in operating activities totaled ($1,045,869).

Net loss for the three months ended September 30, 2009, was ($613,760) or ($0.0036) per share compared to ($1,403,010) or ($0.0832) per share for the comparable period a year ago. Net loss for the first nine months of 2009 was ($1,528,389) or ($0.0090) compared to ($4,893,542) or ($0.0225) per share in the same period a year ago. The reduction reflects the successful implementation of a plan to streamline operations and reduce expenses combined with the increase in revenue for both periods.

As at September 30, 2009, the Company's working capital position includes the short-term portion of a promissory note payable in connection to the previously announced business acquisition. Working capital totaled ($1,638,748) including cash and cash equivalents of $686,227 compared to $2,370,848 in working capital, which included cash and cash equivalents of $1,510,759, at December 31, 2008.

The Company had 203,919,399 common shares outstanding (fully diluted) at June 30, 2009.

Source:

APTILON CORPORATION

Posted in:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Food-as-medicine could save billions in healthcare costs—here’s what’s standing in its way